Melanoma‐associated antigens recognized by cytotoxic T lymphocytes
Authors:
Abstract
During the last 7 years significant progress has been made in the identification of melanoma‐associated antigens recognized by cytotoxic T lymphocytes (CTL). These antigens belong to three main groups: cancer/testis‐specific antigens (MAGE, BAGE, GAGE, PRAME and NY‐ESO‐1), melanocyte differentiation antigens (tyrosinase, Melan‐A/MART‐1, gp 100, TRP‐1 and TRP‐2), and mutated or aberrantly expressed antigens (MUM‐1, CDK 4, β‐catenin, gp 100‐in4, p15 and N‐acetylglucosaminyl‐transferase V). In this review we have summarized the available data concerning the characterization of melanoma‐associated antigens, focusing on their immunogenic and protective properties. The development of a strong immune response to differentiation antigens is limited by the existence of tolerance to these “self” ‐antigens, permitting the involvement of only T cells with low affinity T‐cell receptors. Among the melanoma differentiation antigens, only gp 100 has been shown to be a tumor regression antigen. The cancer/testis‐specific antigens such as MAGE and PRAME should potentially be highly immunogenic antigens. They contain several potential HLA class I binding epitopes and are present only in the testes, which are not accessible to the cells of the immune system owing to the lack of direct contact with the immune cells and the lack of HLA class I expression on the surface of germ cells. But only two patients have been found who responded to these antigens in vivo, indicating their genuinely low immunogenicity. A comparison of the predicted secondary structures of these two groups of antigens (cancer/testis‐specific and differentiation antigens) revealed enrichment of long α‐helical stretches in the cancer/testis‐specific antigens. We hypothesize that such highly organized stable structures could, first, reduce denaturation of the protein and, thus, ubiquitinylation as a degradation signal, and, second, diminish the efficiency of the protein unfolding – a necessary step in the proteolytic cleavage by proteasomes. High structural stability could therefore be responsible for the low immunogenicity of these proteins. In this case, modifications decreasing the stability of these proteins might be a means of improving the immune response to these potentially therapeutically useful antigens.Keywords
This publication has 78 references indexed in Scilit:
- Infrequent expression of the MAGE gene family in uveal melanomasInternational Journal of Cancer, 1996
- Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifsImmunology Today, 1996
- A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytesEuropean Journal of Immunology, 1996
- Structure and Expression of the Mouse Necdin GeneJournal of Biological Chemistry, 1996
- Expression of MAGE genes in primary and metastatic cutaneous melanomaInternational Journal of Cancer, 1995
- Expression of the MAGE gene family in human lymphocytic leukemiaCancer Immunology, Immunotherapy, 1995
- Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I moleculesImmunity, 1995
- Expression of mage genes in transitional‐cell carcinomas of the urinary bladderInternational Journal of Cancer, 1995
- Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selectionEuropean Journal of Immunology, 1995
- Structure, chromosomal localization, and expression of 12 genes of the MAGE familyImmunogenetics, 1994